Citi lowered the firm’s price target on Abbott to $119 from $128 and keeps a Buy rating on the shares. The firm says the Q1 earnings season volatility creates opportunity in the medical technology space. The U.S. hospital capital purchasing environment is stable and China remains a point of volatility through anti-corruption policies and stimulus packages, the analyst tells investors in a research note. Citi left Boston Scientific (BSX) as a top pick while removing Irhythm Technologies (IRTC) and Intuitive Surgical (ISRG). The firm also added GE HealthCare (GEHC) as it recovers from a Q1 low and Insulet (PODD) as it expects a stronger second half of 2024 and momentum into 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABT:
- Abbott call volume above normal and directionally bullish
- FDA posts Class I recall of Abbott HeartMate 3 LVAS implant kit
- Evercore ISI removes several healthcare names from ‘Tactical Outperform’ list
- Abbott Labs EVP of Finance Robert Funck Retires After 36 Years
- Abbott’s dissolving stent receives FDA approval for arteries below the knee